Literature DB >> 29425812

Assessment of the Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) scleral lens on visual acuity for corneal irregularity and ocular surface disease.

Andres S Parra1, Bryan M Roth1, Taylor M Nguyen1, Li Wang1, Stephen C Pflugfelder1, Zaina Al-Mohtaseb2.   

Abstract

PURPOSE: To describe changes in visual acuity in patients fit with the Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) with irregular corneas compared to those with ocular surface disease, as well as describe patient demographics and fitting indications for PROSE at an academic medical center.
METHODS: A retrospective chart review from 2010 to 2016 on a total of 825 eyes from 493 patients fitted with a PROSE lens, and grouped by etiology, either irregular cornea/dystrophy or ocular surface disease and associated sub-etiologies. We compared best corrected visual acuity (BCVA) before and after PROSE fitting.
RESULTS: The irregular cornea group (n = 262 eyes) included corneal scar (n = 57), dystrophy (n = 17), post-operative corneal irregularity (n = 70), and primary ectasia (n = 118). The OSD group included 563 eyes. For all etiologies combined, mean BCVA prior to PROSE fitting compared to after improved by 0.28 logMAR (p < .001). In the irregular cornea group, the mean BCVA improved by 0.46 logMAR (p < .001), while the improvement in BCVA for the OSD group was 0.20 logMAR (p < .001). All etiologies in the irregular cornea group demonstrated improvement in BCVA (p < .05) with the exception of post-PRK (n = 2). BCVA improvement was found for all sub-etiologies in the OSD subgroup (p < .05).
CONCLUSIONS: PROSE treatment had a positive impact on visual acuity for a wide range of corneal irregularities and ocular surface disease, suggesting that PROSE lenses may offer improvements in visual acuity without risks inherent to surgery.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Corneal irregularity; Ocular surface disease; Scleral lens; Visual acuity

Mesh:

Year:  2018        PMID: 29425812     DOI: 10.1016/j.jtos.2018.01.003

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  7 in total

1.  Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization.

Authors:  Jia Yin; Deborah S Jacobs
Journal:  Ocul Surf       Date:  2018-11-20       Impact factor: 5.033

2.  Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis.

Authors:  Sébastien Roumeau; Frédéric Dutheil; Vincent Sapin; Julien S Baker; Stephanie L Watson; Bruno Pereira; Frédéric Chiambaretta; Valentin Navel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-07       Impact factor: 3.535

Review 3.  A Review of the Diagnosis and Treatment of Limbal Stem Cell Deficiency.

Authors:  Anahita Kate; Sayan Basu
Journal:  Front Med (Lausanne)       Date:  2022-05-25

4.  Glaucoma Prevalence and Glaucoma Surgical Considerations in Prosthetic Replacement of the Ocular Surface Ecosystem Device Use.

Authors:  Andrew T Duong; Monica K Ertel; Sarah H Van Tassel
Journal:  Eye Contact Lens       Date:  2022-02-01       Impact factor: 2.018

5.  Clinical outcomes and complications of fluid-filled scleral lens devices for the management of limbal stem cell deficiency.

Authors:  Clémence Bonnet; Andrew Lee; Vivian P Shibayama; Chi-Hong Tseng; Sophie X Deng
Journal:  Cont Lens Anterior Eye       Date:  2021-10-30       Impact factor: 3.946

6.  Scleral lens for severe dry eye status post lacrimal gland resection for adenoid cystic carcinoma.

Authors:  Daniel J Oh; Raman Michael; Pete Setabutr; Ellen Shorter
Journal:  Am J Ophthalmol Case Rep       Date:  2020-01-24

7.  Large diameter scleral lens benefits for Asians with intractable ocular surface diseases: a prospective, single-arm clinical trial.

Authors:  Jayoon Moon; Sang-Mok Lee; Joon Young Hyon; Mee Kum Kim; Joo Youn Oh; Hyuk Jin Choi
Journal:  Sci Rep       Date:  2021-01-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.